Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Europese consensusaanbevelingen voor oligo-gemetastaseerd slokdarm-/maagcarcinoom
feb 2024 | Maag-darm-leveroncologie